Meta AnalysisID 7165
激素避孕与骨代谢
CRD42023460827
Primary Aim What is the effect in terms of changes in OC levels in healthy women of childbearing age when comparing controls and various combinations of estrogen-progestogen therapy, including those preparations with nat
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7165
- Evidence Id
- 15723
- Core Evidence Id
- 15723
- Source Meta Analysis Id
- 7148
- Herb2 Meta Analysis Id
- HBMA007148
- Crd Id
- CRD42023460827
- Title
- Hormonal contraception and bone metabolism
- Review Question
- Primary Aim What is the effect in terms of changes in OC levels in healthy women of childbearing age when comparing controls and various combinations of estrogen-progestogen therapy, including those preparations with natural estrogens? Secondary Aims 1) What is the effect in terms of CTX, P1NP, NTX, PYD, DPD, calcium, ALP, sclerostin, and TRAcP 5b levels in healthy women of childbearing age, when comparing controls and various combinations of estrogen-progestogen therapy, including those with natural estrogens? 2) What is the effect in terms of changes in bone markers metabolism in women of childbearing age with specific conditions (e.g., oligomenorrhea, etc.) when comparing controls and various combinations of estrogen-progestogen therapy, including those preparations with natural estrogens? 3) What estrogen-progestogen therapy-related factors influence bone markers in patients of childbearing age when comparing controls and various combinations of estrogen-progestogen therapy, including those preparations with natural estrogens?
- Study Type Included
- RCT or prospective studies
- Condition Being Studied
- Oral contraceptives are used by many women around the world. Combined oral contraceptives (COCs) can be used both for contraceptive purposes and therapeutic purposes in cases of PCOS and abnormal bleeding [1]. The close relationship between estrogen and bone metabolism is known. This relationship is of greatest concern in adolescent girls [2]. Some data suggest that COCs may inhibit the development of peak bone mass, particularly if started during adolescence [3]. The onset of COC in the early years after menarche would appear to be a major determinant of impaired bone mass acquisition. It is unclear whether the impact on bone depends on the type of estrogen used and its dose [3]. On the other hand, it is known that the decrease in endogenous levels of estradiol that occurs in menopause is a factor that contributes to the development of osteoporosis. Estradiol, in fact, slows down the rate of bone remodeling and protects against bone loss [4]. Bone loss emerges from an imbalance between bone-resorbing osteoclasts and bone-forming osteoblasts. The etiology of this imbalance depends on the risk factors present in the patient. Bone remodeling can be assessed by bone turnover markers [5, 6].
- Participant
- Women of childbearing age
- Animal
- Human Disease Modelled
- Intervention
- Estrogen-progestogen therapy
- Comparator Control
- Pre-post treatment modification Other estrogen-progestogen therapy
- Main Outcome
- Osteocalcin (OC) Measures of effect Assessment of osteocalcin (OC) levels before and after treatment or in controls
- Outcome Measure
- Additional Outcome
- CTX, P1NP, NTX, PYD, DPD, calcium, ALP, sclerostin, and TRAcP 5b levels. In the included studies also bone mass assessment will be analyzed. Measures of effect Assessment of CTX, P1NP, NTX, PYD, DPD, calcium, ALP, sclerostin, and TRAcP 5b levels and bone mass before and after treatment or in controls.
- Study Method
- Systematic review
- Keyword
- Calcium, Dietary; Estrogens; Female; Hormonal Contraception; Humans; Oligomenorrhea; Progestins; Tartrate-Resistant Acid Phosphatase
- Contact
- Ambrogio P Londero [email protected]
- Organisational Affiliation
- University of Genoa www.unige.it
- Funding Source
- None to declare Grant number(s) State the funder, grant or award number and the date of award None to declare
- Other Selection Criteria
- Final Publication
- Same Topic Review
- None found
- Published Protocol
- Review Type
- Language
- English
- Country
- Italy
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-09-05
- Registration Date
- 2023-09-16
- Anticipated Start Date
- 2023-09-11
- Anticipated Completion Date
- 2024-03-31
- Title Cn
- 激素避孕与骨代谢
- Title En
- Hormonal contraception and bone metabolism
- Bilingual Status
- complete